Pain, Acute Clinical Trial
Official title:
A Single-Dose, Comparative Bioavailability Study of Two Formulations of Ibuprofen and Pseudoephedrine Hydrochloride 200 mg/30 mg Tablets Under Fasting Conditions
Verified date | February 2018 |
Source | Institut für Pharmakologie und Präventive Medizin |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Evaluation of the comparative bioavailability between two oral formulations containing ibuprofen 200 mg and pseudoephedrine 30 mg after a single dose in healthy subjects under fasting conditions.
Status | Completed |
Enrollment | 66 |
Est. completion date | May 5, 2014 |
Est. primary completion date | May 5, 2014 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Healthy, non-smoking, male and female subjects, 18 years of age or older. 2. BMI = 18.5 and 30.0 kg/m2 3. No clinically significant findings in vital signs measurements. 4. No clinically significant abnormal laboratory values. 5. No clinically significant findings in a 12-lead electrocardiogram (ECG). 6. No significant diseases. 7. Willing to use an acceptable, effective method of contraception. 8. Be informed of the nature of the study and give written consent prior to any study procedure. 9. Have no clinically significant findings from a physical examination. Exclusion Criteria: 1. Known history or presence of any clinically significant medical condition. 2. Known or suspected carcinoma. 3. History or presence of ulcerative colitis, diverticulosis, Crohn's disease, or gastrointestinal ulcer, perforation, or haemorrhage. 4. Known history or presence of auto-immune disorders, gastrointestinal toxicity, or a risk of gastrointestinal bleeding or gastrointestinal tract irritation. 5. Known history or presence of cardiovascular disease, heart failure, tachycardia, hypertension, angina pectoris, hyperthyroidism, psychosis, seizures, risk of urinary retention, diabetes, phaeochromocytoma, closed angle glaucoma, chronic rhinitis, or prostatic enlargement. 6. Known history or presence of angioedema. 7. Known history or presence of galactose or fructose intolerance, sucraseisomaltase insufficiency, Lapp lactase insufficiency, galactosemia, or glucose-galactose malabsorption syndrome. 8. Known history of severe skin reactions (e.g. exfoliative dermatitis, SJS, and TEN). 9. Known history or presence of bronchial asthma or allergic disease resulting in bronchospasm. 10. Presence of hepatic or renal dysfunction. 11. Presence of clinically significant gastrointestinal disease or history of malabsorption within the last year. 12. Presence of a medical condition requiring regular medication (prescription and/or over-the-counter) with systemic absorption. 13. History of drug or alcohol addiction requiring treatment. 14. History of gastrointestinal bleeding or perforation when previously taking NSAIDs. 15. Positive test result for HIV, Hepatitis B surface antigen or Hepatitis C antibody. 16. Positive test result for urine drugs of abuse (cannabinoids, opiates, amphetamines, cocaine, phencyclidine, tricyclic antidepressants, barbiturates, methadone and benzodiazepines) or urine cotinine. 17. Difficulty fasting or consuming standard meals. 18. Does not tolerate venipuncture. 19. Use of tobacco or nicotine-containing products within 6 months prior to drug administration. 20. On a special diet within 30 days prior to drug administration (e.g., liquid, protein, raw food diet). 21. Participated in another clinical trial or received an investigational product within 30 days prior to drug administration. 22. Donation or loss of whole blood (including clinical trials): - 50 mL and = 499 mL within 30 days prior to drug administration - 500 mL within 56 days prior to drug administration. 23. Females who: Have discontinued or changed the use of implanted, intrauterine, intravaginal, or injected hormonal contraceptives within 6 months prior to dosing; Have discontinued or changed the use of oral or patch hormonal contraceptives within 1 month prior to drug administration; Are pregnant (serum hCG consistent with pregnancy); or Are lactating. 24. Have had a tattoo or body piercing within 30 days prior to drug administration. 25. Known history or presence of hypersensitivity or idiosyncratic reaction to ibuprofen, pseudoephedrine, NSAIDs, or any other drug substances with similar activity or any of the excipients in the drug products 26. Use of drugs in the phenethylamine and amphetamine chemical classes within 14 days prior to drug administration. 27. Use of NSAIDs (including cyclo-oxygenase-2 selective inhibitors) aspirin, corticosteroids, anticoagulants, selective serotonin-reuptake inhibitors, antihypertensives, diuretics, cardiac glycosides, lithium, methotrexate, cyclosporin, mifepristone, tacrolimus, zidovudine, linezolid, dopaminergic alkaloids, quinolone antibiotics, terpene derivatives, clobutinol, atropine, local anaesthetics, MAO inhibitors, vasoconstrictors, alpha sympathomimetic drugs, or anti-platelet agents within 30 days prior to drug administration. 28. Use of any drugs known to induce or inhibit hepatic drug metabolism within 30 days prior to drug administration. (e.g. barbiturates, carbamazepine, phenytoin, glucocorticoids, omeprazole, antidepressants (SSRI), cimetidine, diltiazem, macrolides, imidazoles, neuroleptics, verapamil, fluoroquinolones, antihistamines). |
Country | Name | City | State |
---|---|---|---|
Canada | Pharma Medica Research Inc. | Toronto | Ontario |
Lead Sponsor | Collaborator |
---|---|
Institut für Pharmakologie und Präventive Medizin | Pharma Medica Research, Inc. |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | AUC(0-t) (area under the analyte concentration versus time curve) of ibuprofen and pseudoephedrine, respectively | The 90% confidence intervals of the relative mean plasma (1S,2S)- pseudoephedrine and (S) ibuprofen AUC should be between 80.00 and 125.00% | 7 days (± 3 hours) | |
Primary | maximum serum concentration of ibuprofen and pseudoephedrine, respectively | The 90% confidence intervals of the relative mean plasma (1S,2S)- pseudoephedrine and (S) ibuprofen Cmax should be between 80.00 and 125.00% | 7 days (± 3 hours) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05396820 -
Adaptation of the Motor System to Experimental Pain
|
N/A | |
Completed |
NCT04356963 -
Adjunct VR Pain Management in Acute Brain Injury
|
N/A | |
Recruiting |
NCT06350084 -
Effect of Mother's Touch and Nurse's Therapeutic Touch on Pain Level and Crying Time During Heel Blood Collection
|
N/A | |
Completed |
NCT04080037 -
Assessing Opioid Care Practices Using CPV Patient Simulation Modules
|
N/A | |
Recruiting |
NCT05458037 -
RCT of Pain Perception With Fast and Slow Tenaculum Application
|
N/A | |
Completed |
NCT04571515 -
Dose-Response Study of MR-107A-01 in The Treatment of Post-Surgical Dental Pain
|
Phase 2 | |
Completed |
NCT06005480 -
Understanding Rebound Pain After Regional Anesthesia Resolution in Healthy Volunteers
|
Phase 1 | |
Active, not recruiting |
NCT04850079 -
EHR Precision Drug Treatment in Neonates
|
||
Completed |
NCT03272139 -
Interscalene Block Versus Superior Trunk Block
|
Phase 4 | |
Completed |
NCT03271151 -
Effect of Duloxetine on Opioid Use After Total Knee Arthroplasty
|
Phase 4 | |
Recruiting |
NCT05383820 -
Effect of Paracetamol and Ketorolac on RANK-L Levels in Patients Starting Orthodontic Treatment
|
Phase 4 | |
Completed |
NCT04851353 -
Multiple Sensory Interventions On Infants' Pain and Physiological Distress During Neonatal Screening Procedures
|
N/A | |
Completed |
NCT03280017 -
Ketamine With Multilevel Paravertebral Block for Post Video-assisted Thoracic Surgery Pain
|
Phase 4 | |
Completed |
NCT04280796 -
Changes in Affective Pain Processing in Human Volunteers
|
N/A | |
Not yet recruiting |
NCT04523623 -
Pain Control Differences Between Oxycodone and Ibuprofen in Children With Isolated Forearm Injuries
|
N/A | |
Not yet recruiting |
NCT04491630 -
COping With PAin Through Hypnosis, Mindfulness and Spirituality
|
N/A | |
Not yet recruiting |
NCT04062513 -
Olfactive Stimulation Interventions With Mothers' Milk on Preterm Pain Response
|
N/A | |
Withdrawn |
NCT03137017 -
A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of a New and a Marketed Tablet Formulation Under Fasted and Fed Conditions in Healthy Adults
|
Phase 1 | |
Withdrawn |
NCT03137030 -
A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of Different Amounts of Tablets of a New and a Marketed Tablet Formulation in Healthy Adults
|
Phase 1 | |
Completed |
NCT04659395 -
How to Develop a Training Program for Nurses in Ultrasound Guided Femoral Nerve Block
|
N/A |